DOCSLIB.ORG

Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V 2248 Supplementary Drugs and Other Substances Adiphenine Hydrochloride (USAN, rINNM) Adrenalone Hydrochloride (pINNM) ⊗ Uses. The use of aesculus has been reviewed;1,2 although there is some evidence suggesting benefit in chronic venous insuffi- Adiphénine, Chlorhydrate d’; Adiphenini Hydrochloridum; Adrénalone, Chlorhydrate d’; Adrenaloni Hydrochloridum; ciency, more rigorous studies are needed.2 Cloridrato de Adifenina; Hidrocloruro de adifenina; NSC- Adrenalonu chlorowodorek; Hidrocloruro de adrenalona. 1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and thera- 129224; Spasmolytine. Адреналона Гидрохлорид peutic profile. Pharmacol Res 2001; 44: 183–93. Адифенина Гидрохлорид C H NO ,HCl = 217.6. 2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic ve- 9 11 3 nous insufficiency. Available in The Cochrane Database of Sys- C20H25NO2,HCl = 347.9. CAS — 62-13-5. tematic Reviews; Issue 1. Chichester: John Wiley; 2006 (ac- CAS — 50-42-0. ATC — A01AD06; B02BC05. cessed 31/03/06). ATC Vet — QA01AD06; QB02BC05. Profile Preparations Adiphenine and adiphenine hydrochloride have been used as Profile Proprietary Preparations (details are given in Part 3) antispasmodics. Adrenalone hydrochloride is used as a local haemostatic and va- Arg.: Grafic Retard; Herbaccion Venotonico; Nadem; Venastat; Venostasin; soconstrictor. It has also been used with adrenaline in eye drops Austria: Aesculaforce; Provenen; Reparil; Venosin; Venostasin; Belg.: Preparations for glaucoma. Reparil; Veinofytol; Venoplant; Braz.: Phytovein; Reparil; Varilise; Venafort; Venostasin†; Zarv; Chile: Venastat; Cz.: Reparil; Traumaril†; Venitan; Yellon; Proprietary Preparations (details are given in Part 3) Preparations Fr.: Flogencyl; Ger.: Aescorin Forte; Aescorin N†; Aescusan; Aescuven; Multi-ingredient: Braz.: Analgosedan†; Dipirol†; Dorilen; Doriless; Lisa- Concentrin; Essaven; Essaven Neu; Hamos-Tropfen-S†; Heweven Phyto; dor; Sedalene; Sedalin; Chile: Abalgin; Andil†; Immediat†; SAE; Switz.: Proprietary Preparations (details are given in Part 3) Hoevenol; Noricaven; Opino; opino N; Perivar Rosskaven†; Plissamur; Spasmo-Barbamin†; Spasmo-Barbamine compositum†; Turk.: Spasmo- Denm.: Stryphnon†; Ger.: Stryphnasal†. Proveno N†; Reparil; Rexiluven S†; Sklerovenol N†; Vasoforte N†; Vasot- Panalgine. onin†; Venalot novo†; Venen-Dragees†; Venen-Fluid; Venen-Tabletten; Multi-ingredient: Ger.: Links-Glaukosan†. Venen-Tropfen N; Venentabs; veno-biomo; Venodura; Venoplant; Venopy- ronum; Venopyronum N†; Venostasin; Hong Kong: Reparil; Hung.: Vena- stat; Ital.: Curaven†; Edeven; Flebostasin; Reparil; Mex.: Alevarin; Venastat; Verisan†; Pol.: Aescuven; Esceven; Reparil; Sapoven; Venastat; Venitan; Ven- Adipic Acid Aesculus oplant; Venotonin; Port.: Varison; Venoparil†; Rus.: Venitan (Венитан); Venoplant (Веноплант); Spain: Flebostasin; Plantivenol; Provenen†; Vari- Acide adipique; Acidum adipicum; Adípico, ácido;_ Adipiinihappo; Aesculus hippocastanum; Castaño de indias; Hippocastani se- cid; Switz.: Aesculaforce; AesculaMed; Phlebostasin; Reparil†; Venavit N; Adipinsäure; Adipinsav; Adipinsyra; Adipo rugštis; Hexanedioic men; Horse-chestnut; Marron d’Inde; Rosskastaniensamen. Venostasin; Thai.: Reparil; Turk.: Reparil N; UK: Venaforce; Venez.: Vaso- plant. Acid; Kwas adypinowy; Kyselina adipová. 1,4-Butanedicarboxylic CAS — 6805-41-0 (aescin); 11072-93-8 (β-aescin); 531- acid. 75-9 (anhydrous esculoside). Multi-ingredient: Arg.: Escina Forte; Escina Omega; Esculeol P; Feparil†; Flaval; Grafic Forte; Ixana; Troxeven†; Tubarine; Venoful; Venostasin; VNS C6H10O4 = 146.1. Pharmacopoeias. In Fr., Ger., It., and US. 45; Austral.: Bioglan Cirflo†; Bioglan Zellulean with Escin; Extralife Leg- CAS — 124-04-9. US also includes the powdered form and powdered extract. Care; Herbal Capillary Care†; Proflo†; Austria: Amphodyn; Augentropfen Stulln; Dilaescol; Heparin Comp; Opino; Reparil; Urelium Neu; Venostasin Ger. also includes esculoside in the sesquihydrate form. compositum; Belg.: Mictasol-P; Rectovasol; Reparil; Braz.: Castanha de In- USP 31 (Horse Chestnut). The dried seeds of Aesculus hippoc- dia Composta†; Digestron†; Hemorroidex†; Mirorroidin†; Novarrutina; O astanum (Hippocastanaceae), harvested in the autumn. It con- Proctosan; Reparil; Supositorio Hamamelis Composto†; Traumed†; Vari- tains not less than 3.0% of triterpene glycosides, calculated on zol†; Venocur Triplex; Venofortan†; Venostasin†; Canad.: Proctol; Procto- myxin HC; Proctosedyl; ratio-Proctosone; Chile: Hemorrol†; Proctoplex; HO the dried basis as aescin. Protect from light and moisture. Repariven; Varicare†; Cz.: Anavenol; Evercil†; Heparin-Gel†; Ophthalmo- OH Evercil; Reparil-Gel N; Denm.: Proctosedyl; Fin.: Proctosedyl; Fr.: Aphloine Profile P; Arterase; Climaxol; Creme Rap; Escinogel†; Evarose; Hemorrogel; Histo- O The seeds (conkers) and other parts of the horse-chestnut, Aescu- Fluine P; Intrait de Marron d’Inde P; Mediflor Tisane Circulation du Sang No lus hippocastanum, contain several active principles including 12; Opo-Veinogene; Phlebogel; Phlebosedol†; Phytomelis; Preparation H; Pharmacopoeias. In Eur. (see p.vii). Also in USNF. esculoside (aesculin or esculin; 6-β-D-glucopyranosyloxy-7-hy- Reparil; Sedorrhoide; Veinophytum†; Veinostase; Veinotonyl; Vivene†; Ger.: droxycoumarin, C H O = 340.3) and aescin (escin), which is Aescusan; Amphodyn†; Apoplectal N†; Augentropfen Stulln Mono; Cefa- Ph. Eur. 6.2 (Adipic Acid). A white or almost white, crystalline 15 16 9 sabal; Cycloven Forte N; Diu Venostasin; Essaven N†; Essaven ultra†; Es- powder. Sparingly soluble in water; soluble in boiling water; a mixture of saponins. saven†; Fagorutin Rosskastanien-Balsam N; Hametum-N†; Hamos N†; freely soluble in alcohol and in methyl alcohol; soluble in ace- Ingestion of aesculus may cause nausea, vomiting, diarrhoea, ab- Heparin Comp†; Heparin Kombi-Gel†; Heusin†; Intradermi; Lindigoa S†; opino N spezial†; PC 30 V; Posti N†; Reparil-Gel N; Revicain comp plus†; tone. dominal colic, delirium, and with large doses respiratory arrest. Revicain comp†; Salhumin Teilbad N†; Salus Venen Krauter Dragees N†; USNF 26 (Adipic Acid). A white, crystalline powder. Slightly Aescin and esculoside, the major active principles of aesculus, Solum Ol; Sportupac M; Trauma-cyl; Varicylum-S; Venacton†; Venen Krau- soluble in water; soluble in boiling water and in acetone; freely have been used in the prevention and treatment of various ter NT; Venen-Salbe N†; Venengel†; Veno-Kattwiga N†; Venoplant AHS†; soluble in alcohol and in methyl alcohol. Store in airtight con- Weleda Hamorrhoidalzapfchen; Gr.: Opino-jel; Hong Kong: Proctosedyl†; peripheral vascular disorders, including haemorrhoids (p.1697). Proctosone†; Reparil; Hung.: Reparil N; India: Proctosedyl; Indon.: tainers. They have been given by mouth, by intravenous injection (in the Lanaven; Lanaven Plus; Opino; Irl.: Proctosedyl; Ital.: Algorex; Altadrine; form of sodium aescinate), by rectal suppository, and applied Angiovein; Bres†; Capill; Capill Venogel; Centella Complex; Centeril H; Der- Profile mocinetic; Dermoprolyn†; Edeven; Essaven; Flavion; Flebo-Si; Flebolider; Adipic acid is an acidifier that is used in foods and has been in- topically. Aescin has also been given intravenously in the pre- vention and treatment of postoperative oedema. The maximum Flodolor; Flogofort; Flogovis IdroGel; Hirudex†; Inflamase; Inflamase Idro- cluded in preparations for the treatment of urinary-tract infec- Gel; Levital Plus; Muscoril Trauma; Osmogel; Pik Gel; Proctonet†; Proctop- tions. intravenous dose in adults for such conditions has been stated to ure; Proctosedyl; Recto-Reparil; Reparil; RepaVen†; Sedalen Cort†; be 20 mg daily; acute renal failure has been reported in patients Sedilene Procto†; Signum; Snell Cell; Somatoline; Varicogel†; Venactive; given higher doses, sometimes with other nephrotoxic drugs. Venalta; Venoplus†; Venoton; Venotrauma†; Malaysia: Proctosedyl; Proc- tosone†; Mex.: Almodin; Mon.: Fluon; Norw.: Proctosedyl; Philipp.: Other derivatives such as sodium aescin polysulfate have also Proctosedyl; Pol.: Aesculan; Anavenol; Arcalen; Arnisol; Emorect; Escalar; Adonis Vernalis been used. Fitoven; Hemorol; Neo-Aesculan; Proctosone; Reparil N; Sapoven AT; Sa- poven T; Savarix; Venacorn; Venescin; Venoforton; Venozel; Port.: Relmus Adonide; Adonidis Vernalis Herba; Adonis; Adonis vernal; Adon- Homoeopathy. Aesculus has been used in homoeopathic med- Compositum†; Synchrocell; Venoparil; Rus.: Aescusan (Эскузан); Anaven- icines under the following names: Aesculus hippocastanum; iskraut; False Hellebore; Herba Adonidis; Vernal Pheasant’s Eye; ol (Анавенол); S.Afr.: Essaven†; Proctosedyl; Reparil; Stibium Comp; Sin- Aesculus cortex; Aesculus hippocastanum ex cortice; Aesc. hip. gapore: Erase; Proctosedyl; Spain: Caprofides Hemostatico; Contusin; Es- Ziele miłka wiosennego. savenon; Feparil; Hemodren Compuesto†; Roidhemo†; Ruscimel†; Esculoside has been used in homoeopathic medicines under the Urgenin; Venacol; Swed.: Proctosedyl†; Switz.: Augentonicum; Demoven Pharmacopoeias. In Ger. and Pol. following names: Aesculinum; Aescul. N; Dolo-Veniten†; Flavovenyl; Flogecyl; Ipasin; Lapidar 4; Phlebostasin com- positum†; Reparil; Strath Gouttes pour les veines; Suppositoires contre les Profile Adverse effects. EFFECTS ON THE KIDNEYS. A report of the hemorroides†; Veino-Gouttes-N†; Venoplant comp; Venoplant-N†; Thai.: Adonis vernalis, the dried aerial parts of Adonis vernalis (Ranun- incidence of acute renal failure in patients after cardiac sur- Essaven; Proctosedyl;
Load more

Recommended publications
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub
    US 20150250896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub. Date: Sep. 10, 2015 (54) HYDROPHILIC LINKERS AND THEIR USES Publication Classification FOR CONUGATION OF DRUGS TO A CELL (51) Int. Cl BNDING MOLECULES A647/48 (2006.01) (71) Applicant: Yongxin R. ZHAO, Henan (CN) Ek E. 30.8 C07D 207/216 (2006.01) (72) Inventor: R. Yongxin Zhao, Lexington, MA (US) C07D 40/12 (2006.01) C07F 9/30 (2006.01) C07F 9/572 (2006.01) (73) Assignee: Hangzhou DAC Biotech Co., Ltd., (52) U.S. Cl. Hangzhou City, ZJ (CN) CPC ........... A61K47/48715 (2013.01); C07F 9/301 (2013.01); C07F 9/65583 (2013.01); C07F (21) Appl. No.: 14/432,073 9/5721 (2013.01); C07D 207/46 (2013.01); C07D 401/12 (2013.01); A61 K3I/454 (22) PCT Filed: Nov. 24, 2012 (2013.01) (86). PCT No.: PCT/B2O12/0567OO Cell(57) binding- agent-drugABSTRACT conjugates comprising hydrophilic- S371 (c)(1), linkers, and methods of using Such linkers and conjugates are (2) Date: Mar. 27, 2015 provided. Patent Application Publication Sep. 10, 2015 Sheet 1 of 23 US 2015/0250896 A1 O HMDS OSiMe 2n O Br H-B-H HPC 3 2 COOEt essiop-\5. E B to NH 120 °C, 2h OsiMe3 J 50 °C, 2h eSiO OEt 120 oC, sh 1 2 3. 42% from 1 Bra-11a1'oet - Brn 11-1 or a 1-1 or ÓH 140 °C ÓEt ÓEt 4 5 6 - --Messio. 8 B1a-Br aus 20 cc, hP-1}^-'ot Br1-Y.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Antitnf-Α Strategy: Present Status of This Therapeutic Paradigm J
    Educational Forum AntiTNF-α strategy: Present status of this therapeutic paradigm J. Singh, A. Suruchi Department of ABSTRACT Pharmacology, PGIMS, Tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine is involved in the pathophysiology Rohtak - 124001, India. of a number of disorders including Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. AntiTNF-α strategies target this pathogenic element to provide clinical benefit. Received: 10.2.2003 The various strategies are in preliminary stage of experimentation and much remains to be elucidated Revised: 17.9.2003 before these are applied clinically. Though antiTNF-α therapy is currently approved only for Accepted: 20.9.2003 rheumatoid arthritis and Crohn’s disease, the future of this therapeutic paradigm holds much promise. The number of official indications for strategies against this biologic agent are likely to increase to include congestive heart failure, psoriasis, asthma, septic shock, stroke and malignancy. This will Correspondence to: make it a truly broad spectrum therapeutic weapon currently available to us. J.Singh E-mail: α [email protected] KEY WORDS: AntiTNF- therapy, etanercept, infliximab, tumor necrosis factor. Introduction Clinical strategies for antiTNF-α therapy Tumor necrosis factor-alpha (TNF-α) is a multi-functional AntiTNF strategies are aimed at blocking activity of TNF-α cytokine with important role in immune response, inflamma- either through antiTNF-α antibody or administration of solu- tion and response to injury.1 TNF family is primarily involved ble TNF receptor to mop up circulating TNF-α. In addition to in regulation of cell proliferation and apoptosis.1 TNF-α has these, some proteins, TNF secretion/production inhibitors and also been shown to have an important role in cell death through expression inhibitors are also available11-24 (Table 1).
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome
    Official Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME NCT Number: NCT02701985 Document Dates: Protocol Version 3: 30-Oct-2016 PROTOCOL TITLE: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME PROTOCOL NUMBER: BP30037 VERSION: 3 EUDRACT NUMBER: 2015-004476-30 IND NUMBER: 128528 TEST PRODUCT: RO5459072 SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 28 January 2016 DATE AMENDED Version 2: 01 August 2016 Version 3: See electronic date stamp below FINAL PROTOCOL APPROVAL Approver's Name Title Date and Time (UTC) Translational Medicine Leader 30-Oct-2016 15:40:47 CONFIDENTIAL STATEMENT The information contained in this document, especially any unpublished data, is the property of F.Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. RO5459072— F. Hoffmann-La Roche Ltd Protocol BP30037 Version 3 PROTOCOL AMENDMENT, VERSION 3: RATIONALE Protocol BP30037 has been amended to incorporate the following changes to the protocol: Section 4.2.3: Implementation of changes to eligibility criteria . The eligibility criteria of the protocol have therefore been amended to mandate testing for tuberculosis and exclude patients with positive results.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
    Pure Appl. Chem., Vol. 84, No. 5, pp. 1113–1295, 2012. http://dx.doi.org/10.1351/PAC-REC-11-06-03 © 2012 IUPAC, Publication date (Web): 16 February 2012 IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)* Douglas M. Templeton1,‡, Michael Schwenk2, Reinhild Klein3, and John H. Duffus4 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; 2In den Kreuzäckern 16, Tübingen, Germany; 3Immunopathological Laboratory, Department of Internal Medicine II, Otfried-Müller-Strasse, Tübingen, Germany; 4The Edinburgh Centre for Toxicology, Edinburgh, Scotland, UK Abstract: The primary objective of this “Glossary of Terms Used in Immunotoxicology” is to give clear definitions for those who contribute to studies relevant to immunotoxicology but are not themselves immunologists. This applies especially to chemists who need to under- stand the literature of immunology without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical immunology insofar as they are necessary for a self-contained document, and particularly terms related to diagnos- ing, measuring, and understanding effects of substances on the immune system. The glossary consists of about 1200 terms as primary alphabetical entries, and Annexes of common abbre- viations, examples of chemicals with known effects on the immune system, autoantibodies in autoimmune disease, and therapeutic agents used in autoimmune disease and cancer. The authors hope that among the groups who will find this glossary helpful, in addition to chemists, are toxicologists, pharmacologists, medical practitioners, risk assessors, and regu- latory authorities. In particular, it should facilitate the worldwide use of chemistry in relation to occupational and environmental risk assessment.
    [Show full text]
  • International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
    INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 15/06/2006 INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES (A REVIEW) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM) Department CONTENTS 0. INTRODUCTION…………………………………….........................................................................................v 1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………................................1 2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES…………………….3 2.1 Groups with respective stems ……………………………………………………………………3 2.2 Groups with respective pre-stems………………………………………………………………4 2.3 Groups with INN schemes………………………………………………………………………….4 2.4 Groups without respective stems / pre-stems and without INN schemes…..4 3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………………………………………………………………………...5 3.1 General policies for blood products……………………………………………………………5 3.2 General policies for fusion proteins……………………………………………………………5 3.3 General policies for gene therapy products………………………………………………..5 3.4 General policies for glycosylated and non-glycosylated compounds………...6 3.5 General policies for immunoglobulins……………………………………………………….7 3.6 General polices for monoclonal antibodies………………………………………………..7 3.7 General polices for skin substitutes……………………………………………………………9 3.8 General policies for transgenic products……………………………………………………9
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • A New Venue of TNF Targeting
    Review A New Venue of TNF Targeting Sophie Steeland 1, Claude Libert 2 and Roosmarijn E. Vandenbroucke 1,* 1 Barriers in Inflammation, VIB Center for Inflammation Research, Ghent, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; [email protected] 2 Mouse Genetics in Inflammation, VIB Center for Inflammation Research, Ghent, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; [email protected] * Correspondence: [email protected]; Tel.: +32-9-331-35-87 Received: 31 March 2018; Accepted: 3 May 2018; Published: 11 May 2018 Abstract: The first Food and Drug Administration-(FDA)-approved drugs were small, chemically- manufactured and highly active molecules with possible off-target effects, followed by protein- based medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming increasingly important in the therapeutic landscape. A very prominent class of biologicals are the anti-tumor necrosis factor (TNF) drugs that are applied in several inflammatory diseases that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the treatment of diseases such as Crohn’s disease. However, these inhibitors also have undesired effects, some of them directly associated with the inherent nature of this drug class, whereas others are linked with their mechanism of action, being pan-TNF inhibition. The effects of TNF can diverge at the level of TNF format or receptor, and we discuss the consequences of this in sepsis, autoimmunity and neurodegeneration. Recently, researchers tried to design drugs with reduced side effects. These include molecules with more specificity targeting one specific TNF format or receptor, or that neutralize TNF in specific cells.
    [Show full text]